Merck, Sharp & Dohme LLC submitted a proposal to the Foreign-Trade Zones Board to conduct production activities at its facility in Rahway, New Jersey. The request was reviewed according to the Board's regulations, and the public was invited to comment. On January 16, 2024, the Board decided no further review was needed, and the production activity was authorized under existing regulations. The notification was officially documented on January 16, 2025.
Simple Explanation
Merck, a big company, got permission to make new medicine in a special area in New Jersey without extra checks because everything followed the rules. The dates seem a bit mixed up, which might be a mistake.